April 15, 2019
AstraZeneca’s Japan sales skidded lower in 2018 as it was dented by the first full-year impact from Crestor (rosuvastatin) generic erosions, but it keeps a bright outlook for the country, forging ahead with a plan to achieve four launches each...read more